12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-PCS: Phase I data

Preliminary data from 20 healthy male volunteers with baseline LDL-C level >116 mg/dL in a single-blind, placebo-controlled, single-dose escalation, U.K. Phase I trial showed that IV ALN-PCS was well tolerated and dose-dependently decreased LDL-C and PSKC9. The highest of...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >